Monday, 24 August 2015

PhaseRx, Inc. - Product Pipeline Review - 2015

PhaseRx, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the PhaseRx, Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of PhaseRx, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To access full report with TOC, please visit ​PhaseRx, Inc. - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of PhaseRx, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PhaseRx, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the PhaseRx, Inc.’s pipeline products
Reasons to buy
- Evaluate PhaseRx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PhaseRx, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PhaseRx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PhaseRx, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PhaseRx, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PhaseRx, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

SomaGenics Inc. - Product Pipeline Review - 2015

SomaGenics Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the SomaGenics Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of SomaGenics Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To access full report with TOC, please visit ​SomaGenics Inc. - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of SomaGenics Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of SomaGenics Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the SomaGenics Inc.’s pipeline products
Reasons to buy
- Evaluate SomaGenics Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of SomaGenics Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the SomaGenics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of SomaGenics Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of SomaGenics Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of SomaGenics Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Trophogen, Inc. - Product Pipeline Review - 2015

Trophogen, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Trophogen, Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Trophogen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To view the table of contents and know more details, please visit ​Trophogen, Inc. - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of Trophogen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Trophogen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Trophogen, Inc.’s pipeline products
Reasons to buy
- Evaluate Trophogen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Trophogen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Trophogen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Trophogen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Trophogen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Trophogen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Futura Medical Plc - Product Pipeline Review - 2015

Futura Medical Plc - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Futura Medical plc’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Futura Medical plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To view the table of contents and know more details, please visit ​Futura Medical Plc - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of Futura Medical plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Futura Medical plc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Futura Medical plc’s pipeline products
Reasons to buy
- Evaluate Futura Medical plc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Futura Medical plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Futura Medical plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Futura Medical plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Futura Medical plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Futura Medical plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Stratatech Corporation - Product Pipeline Review - 2015

Stratatech Corporation - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Stratatech Corporation’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Stratatech Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To access full report with TOC, please visit ​Stratatech Corporation - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of Stratatech Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Stratatech Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Stratatech Corporation’s pipeline products
Reasons to buy
- Evaluate Stratatech Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Stratatech Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Stratatech Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Stratatech Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Stratatech Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Stratatech Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Sylentis S.A. - Product Pipeline Review - 2015

Sylentis S.A. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Sylentis S.A.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Sylentis S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
To access full report with TOC, please visit ​Sylentis S.A. - Product Pipeline Review - 2015.
Scope
- The report provides brief overview of Sylentis S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sylentis S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sylentis S.A.’s pipeline products
Reasons to buy
- Evaluate Sylentis S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sylentis S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sylentis S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sylentis S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sylentis S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sylentis S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Hadasit Medical Research Services & Development Ltd - Product Pipeline Review - 2015

Hadasit Medical Research Services & Development Ltd - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Hadasit Medical Research Services & Development Ltd’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Hadasit Medical Research Services & Development Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides brief overview of Hadasit Medical Research Services & Development Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Hadasit Medical Research Services & Development Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Hadasit Medical Research Services & Development Ltd’s pipeline products
Reasons to buy
- Evaluate Hadasit Medical Research Services & Development Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Hadasit Medical Research Services & Development Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Hadasit Medical Research Services & Development Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Hadasit Medical Research Services & Development Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hadasit Medical Research Services & Development Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Hadasit Medical Research Services & Development Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###